Avedro CEO Muller Answers Questions About The FDA’s Questions
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 039″]
David Muller, CEO of Avedro, addresses delays in the FDA’s review of the company’s riboflavin ophthalmic solution/KXL System for corneal cross-linking and discusses the considerable potential of PIXL.
Podcast Guest
David Muller, PhD
Dr. Muller recognized the potential of using advanced methods to gently reshape the cornea and in 2007 founded Avedro, Inc., where he serves as the CEO. Under his direction, Avedro has pioneered numerous advances in the field of cross-linking, including accelerated cross-linking, pulsed illumination, Lasik Xtra, and photorefractive intrastromal cross-linking (PiXL).